In vitro chemosensitivity of gastric adenocarcinomas to histone deacetylase inhibitors, compared to established drugs

Hepato-Gastroenterology

Volumn 57, Issue 99-100, 2010, Pages 657-662

  Yoon, Sang Nam ^a   Roh, Seon Ae ^a   Cho, Dong Hyung ^a   Kim, Moon Bo ^a,b   Hyun, Young Lan ^a,b   Ro, Seonggu ^a,b   Kim, Byung Sik ^a   Kim, Seon Young ^a,c   Kim, Yong Sung ^a,c   Kim, Jin Cheon ^a  

^a University of Ulsan College of Medicine   (South Korea)

^b Asan Medical Center   (South Korea)

^c Korea Research Institute of Bioscience and Biotechnology (KRIBB)   (South Korea)

Author keywords

Chemosensitivity; Gastric adenocarcinomas; Histoculture drug response assay (HDRA); Histone deacetylase inhibitor

Indexed keywords

ANTINEOPLASTIC AGENT; BELINOSTAT; CA 72 4 ANTIGEN; CARBOHYDRATE ANTIGEN; CG 2; CISPLATIN; DOCETAXEL; FLUOROURACIL; HISTONE DEACETYLASE INHIBITOR; PACLITAXEL; TS 1; UNCLASSIFIED DRUG; VORINOSTAT;

ADULT; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CLASSIFICATION; CANCER INHIBITION; DRUG EFFICACY; DRUG POTENTIATION; DRUG SENSITIVITY; FEMALE; HUMAN; HUMAN TISSUE; IN VITRO STUDY; MAJOR CLINICAL STUDY; MALE; PREOPERATIVE PERIOD; PRIORITY JOURNAL; STOMACH ADENOCARCINOMA; TISSUE CULTURE;

ADENOCARCINOMA; ADULT; AGED; CELL PROLIFERATION; FEMALE; HISTONE DEACETYLASE INHIBITORS; HUMANS; MALE; MIDDLE AGED; STOMACH NEOPLASMS;

EID: 77955502396     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Parkin DM, Bray F, Ferlay J, Pisani P: Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74-108.
2. Coombes RC, Schein PS, Chilvers CE, Wils J, Beretta G, Bliss JM, Rutten A, Amadori D, Cortes-Funes H, Villar-Grimalt A, et al.: A randomized trial comparing adjuvant fluorouracil, doxorubicin, and mitomycin with no treatment in operable gastric cancer. International Collaborative Cancer Group. J Clin Oncol. 1990;8:1362-1369.
3. Meyerhardt JA, Fuchs CS: Adjuvant therapy in gastric cancer: can we prevent recurrences? Oncology (Williston Park). 2003; 17:714-721, 728; discussion 728-719, 732-713.
4. Wagner AD, Grothe W, Haerting J, Kleber G, Grothey A, Fleig WE: Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J Clin Oncol 2006;24:2903-2909.
5. Ajani JA: Optimizing docetaxel chemotherapy in patients with cancer of the gastric and gastroesophageal junction: evolution of the docetaxel, cisplatin, and 5-fluorouracil regimen. Cancer. 2008;113:945-955.
6. Marchion D, Munster P: Development of histone deacetylase inhibitors for cancer treatment. Expert Rev Anticancer Ther. 2007;7:583-598.
7. Glaser KB: HDAC inhibitors: clinical update and mechanism-based potential. Biochem Pharmacol 2007;74:659-671.
8. Wu ZQ, Zhang R, Chao C, Zhang JF, Zhang YQ: Histone deacetylase inhibitor trichostatin a induced caspase-independent apoptosis in human gastric cancer cell. Chin Med J (Engl). 2007;120:2112-2118.
9. Nakada S, Aoki D, Ohie S, Horiuchi M, Suzuki N, Kanasugi M, Susumu N, Udagawa Y, Nozawa S: Chemosensitivity testing of ovarian cancer using the histoculture drug response assay: sensitivity to cisplatin and clinical response. Int J Gynecol Cancer. 2005;15:445-452.
10. Vescio RA, Redfern CH, Nelson TJ, Ugoretz S, Stern PH, Hoffman RM: In vivo-like drug responses of human tumors growing in three-dimensional gel-supported primary culture. Proc Natl Acad Sci U S A 1987;84:5029-5033.
11. Kubota T, Sasano N, Abe O, Nakao I, Kawamura E, Saito T, Endo M, Kimura K, Demura H, Sasano H, et al.: Potential of the histoculture drug-response assay to contribute to cancer patient survival. Clin Cancer Res. 1995;1:1537-1543.
12. Singh B, Li R, Xu L, Poluri A, Patel S, Shaha AR, Pfister D, Sherman E, Goberdhan A, Hoffman RM, Shah J: Prediction of survival in patients with head and neck cancer using the histoculture drug response assay. Head Neck. 2002;24:437-442.
13. Kim JC, Kim DD, Lee YM, Kim TW, Cho DH, Kim MB, Ro SG, Kim SY, Kim YS, Lee JS: Evaluation of novel histone deacetylase inhibitors as therapeutic agents for colorectal adenocarcinomas compared to established regimens with the histoculture drug response assay. Int J Colorectal Dis. 2008.
14. Andreotti PE, Cree IA, Kurbacher CM, Hartmann DM, Linder D, Harel G, Gleiberman I, Caruso PA, Ricks SH, Untch M, et al.: Chemosensitivity testing of human tumors using a microplate adenosine triphosphate luminescence assay: clinical correlation for cisplatin resistance of ovarian carcinoma. Cancer Res. 1995;55:5276-5282.
15. Marks PA, Breslow R: Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug. Nat Biotechnol 2007;25:84-90.
16. Huang C, Ida H, Ito K, Zhang H, Ito Y: Contribution of reactivated RUNX3 to inhibition of gastric cancer cell growth following suberoylanilide hydroxamic acid (vorinostat) treatment. Biochem Pharmacol. 2007;73:990-1000.
17. Zou XM, Li YL, Wang H, Cui W, Li XL, Fu SB, Jiang HC: Gastric cancer cell lines induced by trichostatin A. World J Gastroenterol 2008; 14:4810-4815.
18. Burgess A, Ruefli A, Beamish H, Warrener R, Saunders N, Johnstone R, Gabrielli B: Histone deacetylase inhibitors specifically kill nonproliferating tumour cells. Oncogene. 2004;23:6693-6701.
19. Ocker M, Alajati A, Ganslmayer M, Zopf S, Luders M, Neureiter D, Hahn EG, Schuppan D, Herold C: The histone-deacetylase inhibitor SAHA potentiates proapoptotic effects of 5-fluorouracil and irinotecan in hepatoma cells. J Cancer Res Clin Oncol 2005;131:385-394.
20. Furukawa T, Kubota T, Hoffman RM: Clinical applications of the histoculture drug response assay. Clin Cancer Res. 1995;1:305-311.
21. Hayon T, Dvilansky A, Shpilberg O, Nathan I: Appraisal of the MTT-based assay as a useful tool for predicting drug chemosensitivity in leukemia. Leuk Lymphoma. 2003;44:1957-1962.
22. Moon YW, Choi SH, Kim YT, Sohn JH, Chang J, Kim SK, Park MS, Chung KY, Lee HJ, Kim JH: Adenosine triphosphate-based chemotherapy response assay (ATP-CRA)-guided platinum-based 2-drug chemotherapy for unresectable nonsmall-cell lung cancer. Cancer. 2007;109:1829-1835.
23. Fakhrejahani E, Miyamoto A, Tanigawa N: Correlation between thymidylate synthase and dihydropyrimidine dehydrogenase mRNA level and in vitro chemosensitivity to 5-fluorouracil, in relation to differentiation in gastric cancer. Cancer Chemother Pharmacol. 2007;60:437-446.
24. Ohie S, Udagawa Y, Aoki D, Nozawa S: Histoculture drug response assay to monitor chemoresponse. Methods Mol Med. 2005;110:79-86.
25. Whitehouse PA, Knight LA, Di Nicolantonio F, Mercer SJ, Sharma S, Cree IA: Heterogeneity of chemosensitivity of colorectal adenocarcinoma determined by a modified ex vivo ATP-tumor chemosensitivity assay (ATP-TCA). Anticancer Drugs. 2003;14:369-375.
26. Roukos DH: Current status and future perspectives in gastric cancer management. Cancer Treat Rev. 2000;26:243-255.
27. Mitomi H, Kishimoto I, Amemiya A, Kaneda G, Adachi K, Shimoda T, Takigawa M, Fukui N, Ohkura Y: Advanced gastric cancer showing long-term complete remission in response to S-1 monotherapy: two case reports. Cases J. 2008;1:405.
28. Matono S, Horiuchi H, Kishimoto Y, Sasahara H, Ureshino M, Kashihara M, Sueyoshi S, Shirouzu K: [A case of advanced gastric cancer with giant lymph node metastasis responding to S-1/CDDP neoadjuvant chemotherapy]. Gan To Kagaku Ryoho. 2008;35:1573-1575.
29. Ychou M, Duffour J, Kramar A, Gourgou S, Grenier J: Clinical significance and prognostic value of CA72-4 compared with CEA and CA19-9 in patients with gastric cancer. Dis Markers. 2000;16:105-110.